03:00 PM EST - AEterna Zentaris Inc. : said on Wednesday that its first-quarter loss more than doubled due to higher research and development expenses for its enlarged prostate gland treatment. The biopharmaceuticals company said it lost $10.9 million, or 20 cents a share in the period ended March 31, compared with a loss of $5.1 million, or 10 cents a share, during the same period a year earlier. Revenue for the quarter was $9.7 million, up 5.6 percent from $9.2 million in the same period in 2007. Analysts were expecting a loss of 24 cents a share on revenue of $9.8 million. AEterna Zentaris Inc.
shares T.AEZ are trading unchagned at $1.22.
